Shire PLC (SHPG) Given Average Recommendation of “Buy” by Brokerages
Shares of Shire PLC (NASDAQ:SHPG) have earned an average rating of “Buy” from the twenty-five ratings firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $229.10.
A number of research firms recently issued reports on SHPG. Cantor Fitzgerald set a $222.00 price target on shares of Shire PLC and gave the stock a “buy” rating in a research note on Saturday, July 1st. Stifel Nicolaus reiterated a “buy” rating and set a $245.00 price target on shares of Shire PLC in a report on Wednesday, July 12th. Sanford C. Bernstein restated a “market perform” rating and issued a $210.00 target price on shares of Shire PLC in a report on Thursday, July 13th. BidaskClub cut shares of Shire PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Finally, BTIG Research restated a “buy” rating and issued a $242.00 target price on shares of Shire PLC in a report on Monday, July 17th.
A number of hedge funds have recently made changes to their positions in the stock. HPM Partners LLC bought a new stake in shares of Shire PLC during the first quarter worth about $1,534,000. Laurion Capital Management LP bought a new stake in shares of Shire PLC during the first quarter worth about $10,611,000. Vanguard Group Inc. increased its stake in shares of Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares in the last quarter. Gabelli Funds LLC increased its stake in shares of Shire PLC by 1,000.0% in the first quarter. Gabelli Funds LLC now owns 16,500 shares of the biopharmaceutical company’s stock worth $2,875,000 after buying an additional 15,000 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after buying an additional 1,400,275 shares in the last quarter. Institutional investors own 21.06% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Shire PLC (SHPG) Given Average Recommendation of “Buy” by Brokerages” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/24/shire-plc-shpg-given-average-recommendation-of-buy-by-brokerages.html.
Shire PLC (SHPG) traded down 0.24% on Monday, hitting $163.64. The stock had a trading volume of 1,131,452 shares. Shire PLC has a 52 week low of $158.54 and a 52 week high of $209.22. The firm has a market capitalization of $48.74 billion, a PE ratio of 167.84 and a beta of 1.60.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 EPS for the quarter, beating the consensus estimate of $3.22 by $0.41. The firm had revenue of $3.57 billion during the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The business’s revenue was up 109.0% on a year-over-year basis. During the same period last year, the company posted $2.12 earnings per share. On average, analysts predict that Shire PLC will post $14.81 EPS for the current fiscal year.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.